M. Sc - CEO


Andreas Gerward has an engineering background and a master in economics and Venture Creation from Chalmers University of Technology. Andreas has during the last five years worked actively within early pharma development, previously within infection and since 2014 as the CEO of Stayble. Since joining Stayble Andreas has developed the company from an initial idea through preclinical development to clinical trials in early 2017.



Anders has broad experience in drug development from AstraZeneca with an international network and experience from start-ups both internally within AstraZeneca as well as outside. He has also consulted for biotechs and large pharma companies. Anders is responsible for development of Stayble’s clinical candidate.

M.SC. - VP Business Development


Mattias has extensive experience of running start-ups. His roles have been focused on clinical development and business development. He has experience from early development to large phase II clinical trials and has been able to secure over 7 MEUR in a co-founded biotech start-up. He is currently actively working with the management of Stayble to secure funding and conduct business development.


PHD. - Chairman of the board

Catharina Bäärnhielm

Catharina has a broad experience from a variety of senior positions in the pharmaceutical industry, most recently as VP/Global Project Director, at AstraZeneca. Her experience spans all phases of drug development, from idea to launch. She has extensive knowledge of running collaborations between industry and academia. Current other positions include chairman of Cereno Scientific AB, board member of GU Ventures AB and Senior Advisor Karolinska Institutet.

PHD. – Board member


Jane Buus Laursen is Senior Director Business Development and head of AstraZeneca’s Pharmaceutical Technology & Development Business Development team. She has completed a large number of deals with biotechs, pharma and academia spanning from early stage deal making to late stage business transactions across all of AstraZeneca’s strategic areas including licensing deals, M&A, commercial partnerships as well as divestments of late stage clinical and on-market assets and spin-out of early stage assets.

MD, PhD. - Board member and inventor


With over 100 publications in chronic back pain Kjell is considered one of the world’s most renowned researchers within the area. He holds a professorship at Gothenburg University and works actively in the development of the project conducting most the project’s in vivo studies and supporting the board

M.Sc. - Board member

Pontus Ottosson

Pontus is a board member at Stayble Therapeutics AB and currently serves as Head of Investments at Chalmers Ventures. He previously led P.U.L.S, one of the most successful life science incubator / venture capital firms in Scandinavia, completing exits at a deal value of 1.1 billion SEK. Pontus holds M.Sc. degrees in Mechatronics and Entrepreneurship from Chalmers University of Technology.

M.Sc. - Board member


Patrik is investment manager at Almi Invest, Sweden’s most active venture capitalist investing in start-ups. For the last 20 years, Patrik has worked predominantly in small businesses and smaller corporations as a project manager, managing director and chief operating officer. He also has 10 years’ experience as a board member.

Get in touch

Please do not hesitate to contact us for more information about Stayble Therapeutics or to discuss potential partnering opportunities.